Meters & Monitors

Blood Glucose Meters Current Continuous Monitors Comparison of Available Monitors Various Future Monitors Improving Today's Meters Other Monitors Older Monitors

Future Monitoring

AiMedics A.Menarini Diagnostics Cybiocare OHD InLight Solutions Integrated Applications Kumetrix LighTouch Medical Optiscan Orsense Oxygen Biotherapeutics Sensors For Medicine and Science Sensys Medical Sentek Solianis Sontra SpectRx Visual Pathways

Key

	Non-Invasive
	Semi-Invasive
	Surgical
	Continuous

Orsense Ltd.

OrSense Ltd. is a medical device company based in Israel. Their first product, the NBM 200-G is based on its proprietary Occlusion Spectroscopy technology. Orsense claims this technology overcomes obstacles that have plagued other companies attempting to measure glucose optically through the skin.

OrSense has conducted extensive clinical trials of its non-invasive blood glucose monitors, including hundreds of subjects with diabetes. Their results indicate performance similar to those of invasive glucose monitors on the market today. The NBM-200G may provide tight glycemic control in care settings. The company plans to submit the NBM-200G model for regulatory approval with market entry in late 2008 or 2009.

Their occlusion spectroscopy technology uses a non-invasive optical measurement platform combined with a ring-shaped cuff. The pressure applied by the cuff temporarily stops the blood flow in the finger and a "tissue signal" is measured. When the cuff pressure is removed and blood flow returns, a second measurement generates a strong optical signal for blood, yielding a high signal-to-noise ratio. Analysis of the signal provides the sensitivity necessary to measure blood glucose, hemoglobin, and other analyte concentrations.

OrSense is attempting to develop a second generation monitor, shown below, that can monitor glucose levels in a continuous or intermittent mode.